medigraphic.com

2015, Number 4

<< Back Next >>

Rev Med MD 2015; 6.7 (4)

Irritable Bowel Syndrome, a condition with an integrated approach

Delgado-Quiñones EG, Cervantes-Sánchez P, Hernández-Calderón J, Ramírez-Ramos JK

Language: Spanish
References: 34
Page: 300-306
PDF size: 588.26 Kb.


ABSTRACT

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder (PDT), manifested by abdominal pain and bowel disturbances. Its prevalence in the general population ranges between 5 and 20%, reaching up to 35% depending on the population studied. The abdominal pain or discomfort is the primary symptom. At present it is not known precisely what the pathogenic mechanisms in which IBS occurs are because it is a heterogeneous syndrome. Various factors have been proposed as responsible such as motility disturbances, changes in visceral sensitivity and psychological factors. The diagnosis is prominently clinical, based on Rome III criteria and the careful exclusion of disorders that have similar manifestations. Four subtypes are recognized based on the predominant bowel habit behavior according to the characteristics of stools by shape and consistency. Treatment must be multidisciplinary and personalized for each patient, including dietary advice to reduce the intensity of symptoms in periods of exacerbation.


REFERENCES

  1. Guía Global de la Organización Mundial de Gastroenterología. Síndrome de intestino irritable: una perspectiva mundial. 20 abril de 2009.

  2. Córdova-Pluma VH, et al. Frecuencia de síndrome de intestino irritable en la consulta de medicina interna y cirugía general en tres centros de atención médica de la Ciudad de México. Med Int Mex 2008; 24(2):120-4.

  3. Remes-Troche JM. Actualidades en la fisiopatología del síndrome de intestino irritable: el papel de las infecciones. Med Int Mex 2012; 28(5):461-472.

  4. Schmulson M, Vargas JA, López-Colombo A, Remes- Troche JM, López- Alvarenga JC. Prevalencia y caracterización de los subtipos de SII según los criterios de Roma III, en un estudio clínico, metacéntrico. Reporte del grupo mexicano de estudio para el SII. Revista de Gastroenterología de México 2010; 4(75):427-438.

  5. 5.González-Gamarra RG, et al, Prevalencia del Síndrome de Intestino Irritable en la Población Adulta de Chiclayo durante el año 2011. Rev. Gastroenterol. Perú 2012; 32-4: 381-386.

  6. 6.American Gastroenterological Association. The burden of gastrointestinal diseases. Bethesda, MD: American Gastroenterological Association, 2001.

  7. 7.Mearin F, Síndrome del intestino irritable: nuevos criterios de Roma III. Med Clin (Barc). 2007; 128(9):335-43.

  8. 8.Castañeda-Sepúlveda R, Síndrome de intestino irritable. Medicina Universitaria 2010; 12(46):39-46.

  9. 9.Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Therp 2007; 26:535- 544.

  10. 10.Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM; Walkerton Health Study Investigators. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006 ;131(2):445-450.

  11. 11.Mayer EA, Naliboff BD, Craig ADB. Neuroimaging of the braingut axis: From basic understanding to treatment of functional GI disorders. Gastroenterology 2006;131:1925-1942.

  12. 12.Ritchie J. Pain from distension of the pelvic colon by ainflating a ballon in the Irritable Bowel Syndrome. Gut 1973;14:125-132.

  13. 13.Grupo de trabajo de la guía de práctica clínica sobre el síndrome del intestino irritable. Manejo del paciente con síndrome del intestino irritable. Barcelona: Asociación Española de Gastroenterología, Sociedad Española de Familia y Comunitaria y Centro Cochrane Iberoamericano, 2005.

  14. 14.Vargas-Mendoza, J.E., Manuel-Martínez, A. E. y Elizarraras-Rivas, J, Síndrome del intestino irritable y factores socio-emocionales: ansiedad, depresión y calidad de vida. Centro Regional de Investigación en Psicología, 2012; 6(1): 57-64

  15. 15.Bautista-Cerecedo R, Ortiz-Espinosa RM, Muñoz- Juárez S, Síndrome de intestino irritable en estudiantes de medicina. Revista de la Facultad de Medicina de la UNAM, 2011; 54(3):4-11

  16. 16.Gulewitsch MD, Mental Strain and Chronic Stress among University Students with Symptoms of Irritable Bowel Syndrome. Gastroenterol Res Pract. 2013:20-64.

  17. 17.Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a five-year prospective study. Lancet 1987;1:963-965.

  18. 18.Pozos ME, González FA, Lara D MY, García E S, Cabrales T C, Sánchez R, Aptitud clínica sobre síndrome de intestino irritable en médicos de primer nivel de atención. Revista Medicina, Salud y Sociedad. 2011;1(2):1-10.

  19. 19.Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JWM. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews 2011, Issue 8. Art.

  20. 20.Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications. Gastroenterology 2002, 122:1140- 56.

  21. 21.Mudipalli RS, Remes-Troche JM, Andersen L, Rao SC. Functional chest pain, esophageal or overlapping functional disorder. J Clin Gastroenterol 2007;41:264.

  22. 22.J Schmulson M, El escrutinio diagnóstico limitado puede disminuir el impacto económico directo del síndrome de intestino irritable (SII). Rev Méd Chile 2008; 136: 1398-1405

  23. 23.Guía de Práctica clínica Para el Diagnóstico, Tratamiento del Síndrome de Colón Irritable. México: Secretaría de Salud; 2008.

  24. 24.Zijdenbos IL, de Wit NJ, van der Heijden GJ, Rubin G, Quartero AO. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database of Systematic Reviews 2009, Issue 1. Art.

  25. 25.Zolezzi-Francis A, Las Enfermedades Funcionales Gastrointestinales y Roma III. Rev. Gastroenterol Perú 2007; 27: 177-184.

  26. 26.Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipram versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125:19-31.

  27. 27.Ford A, Talley N, Schoenfeld P, et al. Efficacy of psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2008;103 (suppl 1):S477 (1219).

  28. 28.Ford AC, Talley NJ, Schoenfeld PS, Quigley EA, Moayyedi P. Efficacy of antidepressants and psychological theapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58:367-78.

  29. 29.Grupo de trabajo de la guía de práctica clínica sobre el síndrome del intestino irritable. Guía de Práctica Clínica. Síndrome del Intestino Irritable. Manejo del paciente con síndrome del intestino irritable. Barcelona: Asociación Española de Gastroenterología, Sociedad Española de Medicina de Familia y Comunitaria y Centro Cochrane Iberoamericano; 2005.

  30. 30.Lesbros-Pantoflickova D, Michetti P, Fried M, et al. Meta-analysis: The treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20:1253-69.

  31. 31.Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480- 91.

  32. 32.Pimentel M, Park S, Mirocha J. Effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145:557-63.

  33. 33.Tack J, Fried M, Houghton LA, et al. Systematic review: the efficacy of treatments for irritable bowel syndrome: a European perspective. Aliment Pharmacol Ther. 2006;24:183-205 .

  34. 34.Webb AN, Kukuruzovic RH, Catto-Smith AG, et al. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2007;(4) CD005110.




2020     |     www.medigraphic.com